Phase 1 study of human plasma-derived plasmin (TAL-05-00018) in hemodialysis graft occlusion

This first phase I study of plasmin (human) TAL 05-00018, infused into thrombosed HD grafts, documents safety at all doses and an effective thrombolytic dosage of 24 mg indicating that further investigation into locally delivered plasmin is warranted.